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The purpose of this study was to determine the long­
term results of allogeneic bone marrow transplantation 
for chronic myeloid leukemia. A retrospective analysis 
was carried out of the outcome of 373 consecutive trans­
plants performed at 38 European institutions between 
1980 and 1988 and reported to the registry of the Euro­
pean Group for Blood and Marrow Transplantation. All 
transplants were carried out for first chronic phase of 
chronic myelogenous leukemia using unmanipulated 
marow cells from HLA-identical sibling donors. The 
probability of survival and leukemia-free survival at 8 
years were 54% (95% Cl: 49-59) and 47% (95% Cl: 
4.1-52) respectively. The probabilities of developing 
acute GVHD (1I-IV) at 100 days and chronic GVHD at
4 years after transplant were 47% (95% Cl: 41-53) and 
52% (95% Cl: 46-58) respectively. The probabilities of 
transplant-related mortality and leukemic relapse 8 
years after BMT were 41% (95% Cl: 36-48) and 19% 
(95% Cl: 14-25), respectively. Transplant within 12 
months of diagnosis was associated with reduced trans­
plant-related mortality (34 vs 45%, P = 0,013) and 
resulted in improved leukemia-free survival (52 vs 44%, 
P = 0.03). The probability of relapse was significantly 
reduced in patients who developed chronic GVIID (HR 
= 0.33, P = 0.004). The probability of relapse occurring 
more than 2 years after transplant was increased more 
than five-fold in patients transplanted from a male 
donor (RR = 5.5, P = 0*006). Sixty-seven patients in hem­
atologic remission were studied for residual disease by 
two-step RT/PCR for BCR-ABL mRNA and 61 (91%) 
tested negative. We conclude that bone marrow trans­
plantation can induce long-term survival in approxi­
mately one-half of CML patients; the majority of sur­
vivors have no evidence of residual leukemia cells when 
studied by molecular techniques. The probability of late 
relapse is increased with use of a male donor.
Since its introduction in the early 1970s, bone marrow 
transplantation (BMT) for hematological malignancies has 
gained wide acceptance. It is generally considered as the 
only form of therapy with the capacity to cure chronic mye­
logenous leukemia (CML). During the last decade new 
approaches such as the combined use of cyclosporin A 
(CsA) and methotrexate (MTX) for graft-versus-host dis­
ease (GVHD) prophylaxis have reduced treatment-related 
mortality (TRM) and improved outcome.1*2 
ments such as T cell depletion have advanced our under­
standing of the role donor cells play in the elimination of 
residual leukaemia cells after transplant and have resulted 
in novel treatment strategies for relapse.' 7 The inception 
of centralized data bases, such as the European Group for 
Blood and Marrow Transplantation (EBMT) registry, in the 
late 1970s have made it possible to analyze prognostic vari­
ables in large series of patients for their impact on TRM, 
survival, leukemia-free survival (LFS) and relapse. Knowl­
edge of these parameters can assist in the selection of 
patients for BMT and contribute to improved survival. The 
present study extends a previous analysis of transplant for 
CML in Europe and focuses on the clinical and molecular 
outcome of a subset of 'good risk1 patients transplanted in 
first chronic phase using unmanipulated marrow cells from 
a HLA-identical sibling donor.” Almost 50% of the patients 
survive free of their leukemia after marrow transplant and 
appear to be 'cured'. We draw attention to an increased 
risk of leukemic relapse with the use of male donors and the 
detection of residual leukemia cells by reverse-transcription 
polymerase chain reaction (RT/PCR) in a minority of long­
term survivors.
Patients and methods
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Data collection
A retrospective analysis was carried out of patients reported 
to the data base of the Chronic Leukemia Working Party
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of the HBMT in Leiden between 1980 and 1988, Data were 
collected by questionnaire and included details of patient 
and donor age, sex and histocompatibility, WBC at diag­
nosis, duration of disease at the time of BMT, conditioning 
regimen, GVHD prophylaxis and outcome. The follow- up 
was updated from October 1993.
disease recurrence; patients were censored at the time of 
relapse or at last follow-up.
Patients
The study population is a subset of a previous transplant 
cohort reported by EBMT in I993.H This study focused on 
the long-term outcome of a homogenous group of patients 
transplanted for CML. The present study comprised a 
cohort of 373 patients transplanted in first chronic phase of 
CML from an HLA-identieal sibling donor (male, // = 208; 
female, n = 165) using unmanipulated marrow cells. The 
conditioning regimen included in all cases cyclophospha­
mide and total body irradiation (TBI). Patients conditioned 
with a non-TBI-conditioning regimen were excluded from 
the present analysis. GVHD prophylaxis consisted of CsA 
only (// = 211), CsA/prednisoIone (n = 21) or CsA/MTX 
(n = 141). T cell-depleted transplants and patients receiving 
MTX only as GVHD prophylaxis were excluded from this 
analysis. The median recipient age was 31.0 years (range 
2-50). Three hundred and nineteen patients were older than 
20 years of age and 52 patients were younger. The median 
donor age was 30.5 years (range 1-62), The transplants 
were carried out at 38 Europe an institutions between 1980 
and 1988. The time frame 1980 to 1988 was selected in 
order to allow for a median follow-up of 7 years. The par­
ticipating institutions and the number of patients trans­
planted percenter are listed in Appendix 1. Each team con­
firmed that all patients fulfilling the aforementioned criteria 
had indeed been reported to the EBMT. This study there­
fore represents a consecutive series of patients with CML 
transplanted under similar and standard conditions. Patient 
and donor characteristics are further detailed in Table L
Definition of endpoints
Primary outcome variables, ie survival, leukemia-free sur­
vival (LFS), transplant-related mortality (TRM), acute and 
chronic GVHD and relapse, were all calculated from BMT, 
Leukemia-free survival was delined as survival without 
cytogenetic or hematologic evidence of leukemia. Acute 
and chronic GVHD were classified according to standard 
criteria as previously closeribed.t,Jn Patients were evaluable 
for acute and chronic GVHD if they had survived at least 
10 and 90 days respectively after marrow transplantation. 
Relapse was defined as the detection of Philadelphia- 
positive metaphases in the marrow or abnormal blood/bone 
marrow counts or morphology consistent with CML. Dis­
ease recurrence within 2 years after BMT was classified as 
early relapse; late relapse was delined as recurrence of 
CML more than 2 years post-BMT. Transient relapse was 
diagnosed if there was recurrence of CML, as defined by 
cytogenetic or morphological techniques, which resolved 
spontaneously without therapeutic intervention. Patients 
with transient relapse were analyzed with the non-relapse 
group. TRM was defined as death due to causes other than
Molecular defection of BCR/ABL fusion gene
RT/PCR for the BCR-ABL gene rearrangement was carried 
out on peripheral blood or bone marrow cells of 67 patients 
at eight institutions. All these centers used a sensitive two- 
step PCR approach,11
Statistical analyses
%■
Outcome probabilities were calculated by the Kaplan- 
Meier method and comparisons were made using the log 
rank test.'2 The primary outcome variables were analyzed 
according to patient and donor sex, donor-recipient sex 
combinations, method of GVHD prophylaxis (CsA/MTX 
vs CsA alone vs CsA/prednisolone), patient age (20 \>s >20 
years), donor age (30 vs >30 years), (WBC at diagnosis 
(<30 x 1071 v\v >30 x 10'Vl) and time interval from diag­
nosis to transplant (< 12 months vs >12 months). Variables 
significant in univariate analyses at the P <  0.2 level were 
further examined using proportional hazards regression 
analysis employing a backward stepping procedure to ident­
ify the most statistically significant model. Interaction terms 
were added to the final model, but never reached statistical 
significance. In the analysis of early relapse, patients sur­
viving more than 2 years were censored at 2 years. In the 
analysis of late relapses, all patients surviving less than 2 
years were excluded. Acute and chronic GVHD were 
entered as time-dependent variables. All P values are two- 
sided. 95% confidence intervals are quoted in parentheses.
Results
Overall results
Of the 373 patients who received a transplant between 1980 
and 1988, 203 patients are still alive and 170 have died. 
One hundred and seventy-eight patients arc in continued 
complete remission. The overall actuarial probabilities of 
survival and LFS at 8 years were 53.7% (CM: 49-59) and 
46.7% (Cl: 41-52) respectively (Figure I and 'Fable I ). The 
median LFS was 58 months. The median survival had not 
been attained at a median follow-up of 84 months (range: 
35-154). The overall probability of TRM at 8 years was
40.6% (Cl; 36.46) (Table I and Figure 2). One hundred
and lifty-five patients died a transplant-related death, while 
15 died of relapse. The latest death occurred at 72 months 
post-BMT, The main causes of death were GVHD and 
interstitial pneumonitis. These accounted for 54% of i 
deaths, Twenty-seven patients died more than 2 years after 
transplant. Leukemic relapse accounted for 41% of these 
late deaths. The overall probabilities of developing acute 
GVHD (II-IV) at 100 days and chronic GVHD 
(limited/extensive) at 4 years after transplant were 46.6%
(C l 41-52) and 52.1% (Cl: 45.59) respectively (Table 2).
Relapse of CML occurred in 40 patients. In a furl her seven 
cases a transient cytogenetic relapse was observed. Twenty- 
four patients experienced relapse 2 years after BMT; 16
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Table 1 Unadjusted probabi lilies (± s.e.) for survival, LFS, TRM and relapse al N years after I ILA-ideniieal sibling BMT for CM I- in lirsl 
chronic phase
No, Survival
Overall 373 53.7 ± 3
Recipient sex
Male 208 48.4 ± 4
Female 165 60.4 ± 4
Recipienl-donor sex
M/M 120 49.6 ± 5
M/F 88 46.7 ± 6
F/M 86 56.1 ± 6
F/F 79 65.1 ± 6
GVHD prophylaxis
CsA 21 1 50.3 ± 4
CsA/MTX 141 60.9 ± 4
Other 21 42.3 ± 11
Duration of disease
< 12 months 139 61.1 ±4
£*12 months 222 49.3 ± 3
Recipient age
^20 years 52 69.2 ± 6
>20 years 319 50.8 ± 3
WBC at diagnosis
<*0x 10*71 57 56.5 ± 7
>30 x 1071 272 55.4 ±3
Donor .sex
Male 206 52.3 i  4
Female 167 55.5 ±4
Donor age
ss30 years 181 55.4 ±4
>30 years 181 52.6 ± 4
p
0.027
0.05
0.17 *0.06
0.01
0.09
0.62
0.60
0.61
t f l
46.7 ± 3
40.7 ± 4 
54.3 ± 3
37.9 ±5
44.3 ± 6
47.4 ± 5 
61.7 ± 6
44.7 ± 3 
50.0 ± 5 
42.3 ± I I
51.9 ± 4 
44.2 ±3
63.0 ±7 
43.7 ± 3
5L4±7 
48.0 ± 3
41.9 ± 4 
52.7 ±4
47.1 ±3 
46.4 ± 3
Outcomi
I
0.014
0.027
0.53 *0JS
0.03
0.07
0.45
0.27
0.98
TRM
40.6 ± 3
46.7 ± 4 
34.6 ± 5
43.3 ±5 
49.1 ±6 
38.5 ± 5 
30.0 ± 5
45.5 ±4 
32.9 ±4
46.6 ± 12
34.3 ±4 
44.6 ± 3
28.9 ± 6
42.9 ± 3
37.3 ±7 
39.6 ±3
4M ±4 
40.0 ± 4
37.8 ±4 
45.6 ± 3
P
0.05
0.049
0.013
0.18
0.70
0.74
0.33
Rctapsv
0.10 *fUW
18.9 ±3
23.1 ± 4 
14,3 ±4
31.3 ±6
10.4 ±5 
20.0 ± 6
9.1 ± 4
13.4 ±3
25.6 ± 5
20.7 ± I I
18.8 ± 4
17.8 ±4
9.1 ± 5
2 1.0 ± 3
19.8 ±7 
17.6 ± 3
23.6 ±4 
<■>.7 ± 3
20.8 ±4 
16.4 ± 4
P
v i
0.024
0.07 *(U)2
0.65
0.12
0.51
0.026
0.19
*P value lor comparison between CsA alone and CsA/MTX.
No, indicates the number of patients for which data were available in the registry for analysis.
Years post-BMT
Figure 1 Probability of survival and LFS after ML A-identical sibling 
BMT for CML in first chronic phase.
Years post-BMT
Figure 2 Probability of TRM and relapse after 1 ILA-idontieal sibling 
BMT for CML in lirsl chronic phase.
patients had relapse >2 years post-BMT. The latest docu­
mented relapse was at 6.5 years. The probabilities of 
relapse at 2 anc! 8 years were 10.0% (CI: 7-15) and 18.9%; 
(Cl: 14-25) respectively (Table 1 and Figure 2).
Prognostic variables
Male recipients had significantly lower LFS compared to 
females (40.7 vs 54.3%, P ~ 0.014). This could not be attri­
buted to an increase in acute GVHD and both sexes had a 
similar probability of developing acute GVHD (45.4 vs
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Tublo 2  Unadjusted probabilities (± s.e.) for acute GVHD (li-lV) ill 100 days and chronic GVHD (li mi tod/ex tensive) at 4 years after H LA-¡domical 
sibling B M T  for CML in lirst chronic phase
Outcome
No, Acute GVHD P No. Chronic GVHD P
I)vcra 11 361 46.6 ± 3 230 52.1 ± 3
Recipient sex
M a 1 e 203 45.4 ± 4 129 50.6 ± 5
F e im le 158 48.1 ± 4 0,42 101 53,9 ± 5 0.61
Recipient-donor sex
M /M 1 IK 44.2 ± 5 80 42.0 ± 6
M /F 85 47.0 ±6 49 64.8 ± 7
3 7M 82 53.3 ± 6 0.64 49 49.0 ±7 0.19
i 71 - 76 42.4 ± 6 52 58,3 ± 7
C iV 111  ^ prophylaxis
CsA 204 49.8 ± 4 129 58.5 ± 5
C s A /M T X 135 40.1 ± 4 0.032 (0.0002)« 86 40.7 ± 5 0.14 (0.05 r
( )ther 21 57.1 ± II 15 66.6 ± 12
Duration o f  disease
* 12 months 137 41.2 ± 4 96 46.9 ± 5
'1 2  months 216 5 L6 ± 3 0.079 133 54.4 ± 4 0.38
Recipient age
* 2 0  years 50 45.2 ± 6 »  * « M a 40.8 ±9
2 0  years 309 47.1 ±3 0.63 196 54.1 ± 4 0.59
W BC ¿it diagnosis
■ M) x  1071 55 37.5 ± 7 37 47.5 ± 8
M )x  1071 266 49.8 ± 3 0.078 177 53.7 ±4 0.39
Donor sex
M ale 200 48.0 ± 4 129 44.7 ± 5
Lem a le 161 45.8 ±4 0.33 101 6L3 ± 5 0.036
Donor age
' 30  years 176 46.0 ± 4 115 49.9 ± 5
> 3 0  years 174 48.1 ±3 0.83 1 15 56.8 ± 5 0.20
7' va lue  Tor comparison between CsA alone and CsA/MTX.
No. ind ica tes  the number of patients for which data were available in the registry for analysis.
4X. 1 P  =  0.42). The difference in LFS was explained by Recipient-donor sex combinations impacted significantly
an i n c r e a s e  in both T R M  (45.7 vs 34.6%, P =  0.05) and on transplant outcome after transplant. The LFS o f female
r e la p s e  (23.1 vs 14.3%, P =  0.04) in males. Patient sex recipient-female donor pairs was 61.7% compared to only
r e m a i n e d  a significant variable for both LFS and T R M  in 37.c)%  for male-male pairs with an intermediate outcome
m u l t i v a r i a t e  analysis (Table 3). for sex-mismatched combinations (Figure 3). Female
Tuble 3 Multivariate analyses-'best’ models for various outcomes after siepwise selection procedure
( hitcomc Prognostic variable RR Cl) P vttlue Favorable
I .I ’S" Reci pieni sex 0.65 10.49-0.8HJ 0.0043 Female
AGVHD 0.36 i0.27~0.49) 0.00001 Grade 0 1
TRM Recipient sex 0.64 (0.45-0.90) 0.010 Female
aGVHD 0.25 (0.17-0.37} 0.00001 Grade (M
GVHD prophylaxis 0.71 (0.50-1.01 ) 0.053 CsA/MTX
¿»Cl V I I I ) GVHD prophylaxis 0.70 (0.50-0.97) 0.028 CsA/MTX
Duration of disease 0.75 (0.54-1.03) 0.069 < 12 months
c t iV H D GVHD prophylaxis 0.59 (0.39-0.88) 0.008 CsA/MTX
Relapse Donor sex 0.44 (0.20-0.98) 0.032 Female
cGVHD 0.33 (0.14-076) 0.0044 Limited/extensive
Lari y relapse (=£2 years) eGVHD 0.35 (0.13-0.97) 0.030 Limited/extensive
Late re lapse  (>2 years) Donor sex 0.18 (0.04-0.80) 0.006 Female
cGVHD 0.21 (0.05-0.94) 0.015 Limited/extensive
’LFS is th e  probability of survival without relapse or death.
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female pairs benefited from low TRM (30.0%) and relapse 
rate (9.1%). In contrast male-male pairs did not only have 
increased TRM (43.3%), but also experienced more leu­
kemic relapses (31.3%) (Table 1), However, the probability 
of leukemia relapse was not increased in male-female pairs.
Patients transplanted within 12 months of diagnosis hud 
significantly better LFS (51.9 v.v 44.2%, P - 0.03) which 
was due to a decrease in TRM (34.3 v.v 44.6%, P = 0.013). 
There was a trend towards less acute GVHD if the trans­
plant was carried out within 1 year of diagnosis (41.2 vs 
5 1.6%, P = 0.079). The combined impact of duration of 
disease and GVHD prophylaxis (CsA only vs CsA/MTX) 
on LFS was also studied, but no significant differences 
were observed.
Acute CiVI ID grade II—IV affected LFS adversely in 
multivariate analysis (RR = 0.36, P = 0.00001) which was 
due to a significant increase in TRM (II-IV v.v 0-1, RR = 
4.0). Recipient age did not influence the probabilities of 
acute GVHD IM V  or chronic GVFID. There was a trend 
towards improved survival if the transplant was carried out 
with immunosuppression consisting of CsA/MTX (60,9 vs 
50.3%, P ^ 0.06). I I0 we v e r, the re was no s i g 11 i 1 i e a n t d i fie r- 
ence in LFS (50.0 v.v 44.7%, P ~ 0.18) between the CsA 
and CsA/MTX group. GVHD prophylaxis with CsA/MTX 
reduced both acute GVHD (49.8 v.v 40.1%, P = 0.0002) 
and TRM (45.5 v.v 32.9%-, P = 0.04) in comparison to CsA 
only. In multivariate analysis the risk of developing acute 
GVHD II IV remained reduced in the CsA/MTX group 
(CsA v.v CsA/MTX; RR = 0.7, P = 0.028) anti was also 
associated with less TRM (RR = 0.71, P = 0.53). However, 
the relapse rate in patients treated with CsA/MTX was sig­
nificantly increased (25.6 v.v 13.4%, P = 0.02) (Figure 4). 
There was also a difference in chronic GVHD, but this was 
of borderline significance (P = 0.05).
Chronic GVHD and male donor sex were significant 
independent variables for relapse in the proportional haz­
ards model (Table 3). Chronic GVHD (limited/extensive) 
reduced the relative risk of both early and late relapse (RR 
~ 0.35, P ~ 0.03 and RR = 0.21, P ~ 0.015, respectively). 
Male donor sex was a significant variable for late relapse
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Figure 4 Relapse after HLA-idenlieal sibling BMT for CML in first 
chronic phase according to GVHD prophylaxis.
(RR = 5.5, P = 0.006). Fourteen of the 16 patients with 
late relapse were transplanted from a male donor, The com­
bined influence of these variables was that patients with no 
chronic GVHD and a male donor had an overall probability 
of relapse of 34.9% compared to only 5.1% for those with 
any chronic GVHD and a female donor (P = 0.001) (Figure 
5). The duration of disease prior to transplant did not affect 
relapse, even if the analysis was confined to patients with 
no acute or chronic GVHD. The probabilities of 3-year sur­
vival after early and late relapse had occurred were 38.0% 
(CI. 21-57) and 70% (CI: 44-88), respectively.
RT/PCR for BCR/ABL fusion gene
Sixty-seven patients were studied by two-step RT/PCR for 
BCR-ABL mRNA at a median of 114 months post-BMT 
(range: 34-161). These patients were tested in eight differ­
ent centers (Appendix 1). Sixty-one patients (91%) were 
PCR negative when last tested. Six patients were PCR posi­
tive at 39, 77, 84, 86, 126 and 138 months post-BMT. 
These patients remain in complete remission as defined in 
the Materials and methods section.
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Figure 5 Relapse afler I ILA-identieal sibling BMT for CML in a first 
chronic phase according lo donor sex and chronic GVHD. Group A: male 
donor-no cGVHD {n ~ 73), group B: female donor-no eGVHD (// = 4 1), 
group C: male donor-limited or extensive eGVHD (n = 72) and group D: 
female donor-limited or extensive eGVHD (// = 82).
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Discussion
The present o f  a large, homogeneous of
tance to prevent relapse of CML after marrow transplant. 
It seems reasonable to speculate that the low relapse rate 
in male-female pairs is due to recognition of the Y minor
patients with CML in first chronic phase indicates that alio- histocompatibility antigen on leukemia cells by lymphoid
geneic marrow transplantation results in long-term disease- cells from the female donor. Surprisingly, a low relapse
free survival in nearly half of the patients. This data is simi- rate was also observed in female-female pairs, which
lar to the outcome reported in other large series.1 •*’'4 The could be due to recognition of antigenic differences by
median survival in this study had not yet been attained at female donor cells previously sensitized during
8 years. This compares favorably to median survivals rang- nancy. However, it should be acknowledged that the regis-
ing from 66 to 72 months reported in recent large scale try did not contain details of the pregnancy record of the
studies of patients treated conservatively with interferon- donors which would have for testing of this
a , 15- 17 Furthermore, over 90% of patients tested were nega­
tive for the leukemia-specific BCR-ABL fusion message by We observed that patients who were surviving more
RT/PCR. This is in contrast to the findings during inter- than 2 years post-BMT continued to relapse at a rate of
feron-tt therapy where molecular studies can detect per­
sisting leukemia cells in virtually all patients.18”20 The data 
from this multicentre study support the notion that allo­
geneic marrow transplantation is the only therapy which can 
restore normal hematopoiesis to a substantial number of 
patients with CML.
The present study reports parameters which influence 
LFS and which may assist in the timing of transplant and 
donor selection. Recipient sex and acute GVHD proved to 
be significant determinants of LFS in multivariate analysis. 
Female recipients who did not develop acute GVHD (II- 
IV) post marrow transplant achieved a leukemia-free sur­
vival of nearly 70%. Conversely, a LFS of only 38% was 
observed in male recipients of male donor marrow which 
was due to an increase in both TRM and rate of leukemic 
relapse. The optimal timing of the transplant was found to 
be within 1 year from diagnosis where a small, but signifi­
cant survival benefit was observed, primarily due to a
approximately 1.5% per year until 6.5 years when the last 
relapse was observed. Late relapses after marrow trans­
plant for CML may be more frequent than has 
assumed hitherto. Enright et til12 re
reduction in TRM. we could not
previous findings that this survival benefit was particularly
in patients who received CsA/MTX as GVHD 
prophylaxis.
It has been previously reported that transplantation for 
CML in accelerated or blastic phase carries an increased 
risk of leukemic relapse.8 In the present study, which was 
confined to CML in chronic phase, the probability of leu­
kemic relapse was 19%. Disease-related variables, such as 
WBC at diagnosis, were not associated with relapse, even 
if the analyses were adjusted for the method of GVHD 
prophylaxis and the incidence of acute or chronic GVHD. 
However, chronic GVHD and male donor sex were strongly 
associated with relapse. The probability of relapse for 
patients transplanted with marrow cells from a female 
donor and who developed chronic GVHD was only 5%. In 
contrast, the relapse rate in patients with a male sibling
and no subsequent chronic GVHD reached 35%.
six relapses
more than 5 years post-BMT in a cohort of 179 patients 
transplanted from a sibling donor. These findings imply 
that continued monitoring for late disease recurrence is 
warranted. In our study residual leukemia cells were found 
by RT/PCR for the BCR-ABL gene rearrangement in 
approximately 10% of disease-free survivors. Molecular 
quantification of residual disease in two of these long-term 
survivors confirmed that the leukemic clone persisted at 
low levels more than 10 years after transplant.- However, 
it is at present not certain if these patients indeed harbor 
Philadelphia-positive clonogenic precursor cells and if 
these patients are still at risk of relapse. Recently, atten­
tion has been drawn to the detection of the BCR-ABL 
fusion message in apparently normal individuals. If pro­
ven correct, this observation casts doubt on the signifi­
cance of positive PCR findings in long-term survivors of 
m at* r o w t r a n s d 1 a n t a t i o n. ~4
GVHD and/or interstitial pneumonitis were responsible 
for 54%) of all deaths. The current study confirms that
with CsA/MTX ispost-transplant
more effective in reducing acute GVHD and TRM com­
pared to GVHD prophylaxis with CsA only.1’ Although 
there was a trend towards better survival in the CsA/MTX
not translate into an improved 
LFS due to an increased relapse rate. New therapeutic 
approaches for the management of relapse have become 
available in recent years. The initial experience with adop­
tive immunotherapy consisting of lymphocyte transfusion 
from the original marrow donor suggest that approxi­
mately 70% of patients with relapsing disease can be sal­
vaged. It seems likely therefore that in coming years more
Interestingly, the absence of chronic GVHD was a risk fac- emphasis will be placed on reducing GVHD and acute
tor for both early and late relapse, whilst male donor sex toxicity at the time of the per primum transplant procedure
only increased the risk of late relapse. It was particularly with the option of subsequent immune modulation with
striking that 14 out of 16 patients who relapsed more than donor cells in case of relapse. The present cohort did not
2 years after transplant were transplanted with marrow cells have the benefit of recent advances in the management of
cytomegalovirus infection which is an important cause of 
interstitial pneumonitis after transplant.'Early detection
from a male donor. The increased number of late relapses 
observed with the use of male donors could not only be 
accounted for by a reduction in chronic GVHD for both and effective treatment of reactivation of cytomegalovirus 
factors proved significant in multivariate analysis. These with ganciclovir has now become common practice and
findings support the idea that immunological control of will serve to CMV pneumonitis and further
residual leukemia by donor cells is of paramount impor- improve outcome in future transplant cohorts.
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